

## Dr. Jeffrey Tomaszewski: the application of prostate cancer genomic tests

Submitted May 25, 2016. Accepted for publication Jun 02, 2016.

doi: 10.21037/tau.2016.06.09

View this article at: <http://dx.doi.org/10.21037/tau.2016.06.09>

The 2016 American Urological Association (AUA) Annual Meeting was held grandly in the San Diego Convention Center, USA from May 6th to May 10th. During the annual meeting, many new researches were shared and discussed. This time, the Editorial Office of *Translational Andrology and Urology (TAU)* was honored to invite Dr. Jeffrey Tomaszewski (*Figure 1*), from Cooper Medical School of Rowan University, to have an interview with us.

In the interview, Dr. Tomaszewski interestingly introduced to us some common biomarkers as well as how they work for the prognostication of prostate cancer outcome and prediction of therapeutic response. After the brief introduction for the biomarkers, Dr. Tomaszewski also shared with us his idea about the application of prostate cancer genomic tests to reduce unnecessary prostate biopsies and the morbidity of overtreatment, an important topic in this year's AUA.

When mentioning his idea on the life being an urologist, Dr. Tomaszewski passionately told us his view—the urological field is a broad spectrum and he enjoys it a lot!

Want to know what'll Dr. Tomaszewski do if he were not an urologist? Just click the video (*Figure 2*)!

### Interview questions

- (I) You have joined the session about the use of genomic biomarkers in the prognostication of prostate cancer outcome and prediction of therapeutic response. Would you like to tell us what are the common genomic biomarkers for the prognostication?
- (II) How do these biomarkers work for the prognostication of prostate cancer outcome?
- (III) As an urologist, how to integrate of prostate cancer genomic tests into practice?
- (IV) Also, how to apply prostate cancer genomic tests to reduce unnecessary prostate biopsies and the



**Figure 1** Picture with Dr. Jeffrey Tomaszewski.



**Figure 2** Dr. Jeffrey Tomaszewski: the application of prostate cancer genomic tests (1).

Available online: <http://www.asvide.com/articles/1073>

- morbidity of overtreatment?
- (V) Some people may think the life, as an urologist, is boring while others may think the other way around. Then how do you think about this? What keeps your passion in this career?
- (VI) If you were not an urologist, what will you do?

### Expert introduction

Dr. Jeffrey Tomaszewski is an urologist in Cooper Medical School of Rowan University. He owns membership in many organizations, including the American Society of Clinical Oncology, American Cancer Society, American Urological Association, Society of Urologic Oncology, American Medical Association and so on.

Dr. Tomaszewski specializes in minimally invasive and robotic management of kidney, prostate, bladder, adrenal, testis, penile and ureteral cancer.

### Acknowledgements

None.

**Cite this article as:** Gao S. Dr. Jeffrey Tomaszewski: the application of prostate cancer genomic tests. *Transl Androl Urol* 2016;5(4):626-627. doi: 10.21037/tau.2016.06.09

### Footnote

*Conflicts of Interest:* The author has no conflicts of interest to declare.

### References

1. Gao S. Interview with Dr. Jeffrey Tomaszewski. *Asvide* 2016;3:299. Available online: <http://www.asvide.com/articles/1073>

(Science Editor: Skylar Gao, TAU, [tau@amepc.org](mailto:tau@amepc.org))